Rhesus monkeys infected with the simian immunodeficiency virus of macaques (SICVK) demonstrate significant virologic and clinical improvement as a result of treatment with human recombinant soluble CD4 (rsCD4). We show that human rsCD4 does not efficiently inhibit SIV1 replication in bone marrow macrophages of rhesus monkeys and does not snificantly augment bone marrow hematopoietic colony formation in vitro. However, plasma of human rsCD4-treated rhesus monkeys does exhibit sicant anti-SIV activity in vitro. Plasma of these animals efficiently blocks
in adjuvant demonstrate reactivity with a soluble form of the rhesus monkey CD4 molecule, exhibit binding to CD4' but not CD81 concanavalin A-activated rhesus monkey peripheral blood lymphocytes, and precipitate the CD4 molecule from surface-labeled activated rhesus monkey peripheral blood lymphocytes. Moreover, anti-viral activity is demonstrable in the IgG fraction of plasma from a human rsCD4-immunized monkey. These studies raise the possibility that a modified human CD4 molecule serving as an immunogen might elicit an antibody response that could potentially induce a beneficial therapeutic response in human immunodeficiency virusinfected individuals.
The human CD4 molecule is a high-affinity receptor for the human immunodeficiency virus (HIV) envelope glycoprotein (1) . This has been demonstrated by a number ofexperimental approaches. Monoclonal anti-CD4 antibodies block HIV infection of target cells in vitro (2, 3) . Cells not expressing the CD4 molecule may become susceptible to HIV infection after transfection with the CD4 gene (4) . Moreover, it has been shown (5-9) that a recombinantly produced soluble form of the extracellular portion of the CD4 molecule can block HIV infection of cells in vitro.
These findings led to the suggestion that a soluble form of CD4 may prove valuable in the therapy of HIV-infected individuals. Recombinant soluble CD4 (rsCD4) might be employed for the targeting of toxins to cells infected with HIV that express the HIV envelope glycoprotein on their surfaces (10) (11) (12) . rsCD4 might also inhibit virus infection by directly competing with cell surface CD4 molecules for the binding of HIV. It was this possibility that led us to assess the therapeutic value of rsCD4 in rhesus monkeys infected with the simian immunodeficiency virus of macaques (SIV.).
These studies demonstrated significant virologic and clinical improvement in the SIV,.c-infected monkeys as a result of treatment with human rsCD4 (13) .
In the present studies, we demonstrate that human rsCD4 is inefficient in vitro at mediating many ofthe antiviral effects observed in the rsCD4-treated SIV.-infected rhesus monkeys. However, we show that rhesus monkeys develop an antibody response after treatment with human rsCD4, and this antiserum binds to monkey CD4 and inhibits SIVmic replication in monkey cells.
MATERIALS AND METHODS Animals. Two normal rhesus monkeys (Macaca mulatta)
were treated for 50 days with human rsCD4, each receiving 2 mg intramuscularly (i.m.) daily. Four normal rhesus monkeys were immunized subcutaneously, two with 1 mg of human rsCD4 and two with 1 mg of human serum albumin (HSA) in an emulsion with complete Freund's adjuvant (Sigma) and again by the same route 34 days later with 1 mg of human rsCD4 or 1 mg of HSA in an emulsion with incomplete Freund's adjuvant (Sigma) . The animals were maintained in accordance with the guidelines of the Committee on Animals for the Harvard Medical School and the National Institutes of Health (14) .
rsCD4. Human rsCD4 (Biogen) was produced as described (5) . Rhesus rsCD4, consisting of the N-terminal 375 amino acids ofthe rhesus monkey CD4 molecule, was secreted from Chinese hamster ovary (CHO) cells and purified by a combination of ion-exchange and immunoaffinity chromatographic procedures ( Detection of Anti-Human and Anti-Rhesus Monkey rsCD4 Antibody. Anti-rsCD4 antibody titers were determined by ELISA. Ninety-six-well plates (Nunc) were coated overnight with human or rhesus monkey rsCD4 or HSA at 0.3 gg per well. Plasma samples were added to wells at various dilutions and incubated for 1 hr at room temperature. Horseradish peroxidase-conjugated goat anti-human immunoglobulin (1:2000 dilution, Zymed) was then added and incubated for 2 hr. After washing, 100 kd of 3,3',5,5'-tetramethylbenzidine peroxidase substrate solution (Kirkegaard and Perry, Gaithersburg, MD) was added to each well. After 10 min the reaction was terminated and light absorbance was read at 450 nm on an ELISA reader. In this anti-rsCD4 antibody assay, pooled normal rhesus monkey plasma served as a negative control. A positive ELISA reading was defined as a binding level of twice the mean or mean + 4 SDs above the negative control levels in each assay.
Surface Labeling, Immunoprecipitation, and SDS/PAGE. Lymphoblasts were surface labeled using a water-soluble Bolton-Hunter reagent (17) . Cells were resuspended with 35 mM sodium borate (pH 9.2) and then incubated with sulfosuccinimidyl-3-(4-hydroxy-phenyl)propionate, a watersoluble Bolton-Hunter reagent (Pierce). After a 30-min incubation at 40C, cells were incubated with 0.5 mCi of '25INa (Amersham; 1 Ci = 37 GBq) for 20 min in a vial coated with 100 pg of lodo-Gen (Pierce). After washing, cells were incubated on ice for 30 mm in lysis buffer. The resulting supernatant was precleared and incubated with either a mAb or rhesus monkey plasma. Immunoprecipitation was performed using 3 mg of goat anti-mouse or goat anti-human immunoglobulin bound to microspheres (Kirkegaard and Perry). The microspheres were washed and resuspended in 80 p4 of SDS/PAGE sample buffer. SDS/PAGE was carried out by using the method of Laemmli (18) .
Plasma Fractionation. IgG and non-IgG plasma fractions were prepared from rhesus monkeys immunized with human rsCD4 by using a protein A-Sepharose column. Plasma was applied to a protein A-Sepharose CL-4B (Sigma) column equilibrated in 100 mM Tris.HCl/3 M NaCl, pH 8.9. The column was washed with the same buffer and the non-IgG fraction was recovered. The column was then eluted with 100 mM acetic acid/150 mM NaCl, pH 2.9, and the eluate was dialyzed and concentrated. The IgG fractions of the eluate were identified by absorbance at 280 nM.
RESULTS
We have demonstrated a clinical improvement in SIVMCinfected rhesus monkeys treated with human rsCD4 (13 SIV~c-infected rhesus monkeys also showed improvement in their bone marrow hematopoietic function during rsCD4 treatment. This improvement, an increase in bone marrow granulocyte/macrophage and erythrocyte progenitor cell colonies, probably resulted from the inhibition of SIVNS replication in bone marrow macrophages (16) .
A number of observations made during the course of these studies suggested that rsCD4 may have mediated at least (Table 2) . Interestingly, the plasma of a rsCD4-treated normal rhesus monkey, which contained rsCD4 at' <250 ng/ml, inhibited SIV, replication in both rhesus monkey PBLs and bone marrow macrophages. As shown in Table 1 (Fig. 1) . Moreover, whereas antibody in the plasma of a rhesus monkey prior to initiating treatment did not bind to rhesus monkey PBLs, antibody in the plasma of this monkey after initiation ofrsCD4 treatment clearly bound to CD4+ but not CD8+ Con A-activated rhesus monkey PBLs (Fig. 2) . Such plasma also precipitated the CD4 molecule from surface-labeled Con-Aactivated rhesus monkey PBLs (Fig. 3) . Monkeys treated by a similar schedule with HSA never developed an anti-rsCD4 antibody response (Figs. 1 and 3) . Thus, the immunologic tolerance that the monkey might have been expected to demonstrate to its own' CD4 molecules expressed on the surface of its own cells appears to have been broken by the daily administration of human rsCD4.
We then sought to determine whether antibodies raised in a rhesus monkey conventionally' immunized with rsCD4 might also inhibit SIINS replication. A normal rhesus monkey was immunized with human rsCD4 in an emulsion in complete Freund's adjuvant. Plasma taken from this animal before and after immunization was separated into IgG and non-IgG fractions by protein A column passage. As shown in Table 3 , antibodies in the preimmune plasma of this animal demonstrated no binding to rhesus monkey rsCD4 in an ELISA. This plasma also did not contain antibody that bound to lectin-activated rhesus monkey PBLs. However, immune plasma demonstrated significant anti-rhesus monkey CD4 binding both to lectin-activated monkey PBLs and in an ELISA. This activity was present in the IgG fraction of the immune plasma; the non-IgG fraction of the plasma demonstrated no such reactivity-.
The plasma of the immunized monkey but not the monkey's preimmune plasma inhibited SIVn,, replication in rhesus monkey PBLs and bone marrow macrophages (Table  3 ). This anti-SIV,-activity was contained in the IgG but not in the non-IgG fraction of the immune plasma. The plasma of the animal after immunization but not prior to immunization (19) . Plasma from these individuals could not be shown to bind to activated human The use of specific antibodies as therapeutic agents has been explored in many clinical settings. In the preantibiotic era, specific serotherapy was utilized with some success in the treatment of bacterial illnesses. T-lymphocyte-specific mAbs are currently used in the treatment of acute renal allograft rejections (21) . However, the use of mAbs as therapeutic agents has been limited by their elicitation of anti-mouse immunoglobulin responses (22) . The use of a soluble protein such as rsCD4 to elicit and maintain a specific antibody response might harness the potential therapeutic utility of antibodies while circumventing the problem of "neutralizing" anti-immunoglobulin responses.
